Comparative Pharmacology
Head-to-head clinical analysis: DOXYCYCLINE versus TETRACHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXYCYCLINE versus TETRACHEL.
DOXYCYCLINE vs TETRACHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex. It also exhibits anti-inflammatory and anti-collagenase activities.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg every 12 hours or 50 mg every 6 hours.
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
None Documented
None Documented
Terminal elimination half-life is 18–24 hours in patients with normal renal function; prolonged to 20–30 hours in renal impairment; allows once or twice daily dosing.
Clinical Note
moderateMethoxsalen + Doxycycline
"The metabolism of Doxycycline can be decreased when combined with Methoxsalen."
Clinical Note
moderateCyclophosphamide + Doxycycline
"The metabolism of Doxycycline can be decreased when combined with Cyclophosphamide."
Clinical Note
moderatePaclitaxel + Doxycycline
"The metabolism of Doxycycline can be decreased when combined with Paclitaxel."
Clinical Note
moderateDocetaxel + Doxycycline
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Renal (40%) and fecal/biliary (60%); undergoes enterohepatic circulation; active drug and metabolites excreted in urine and feces.
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Category D/X
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic
"The metabolism of Doxycycline can be decreased when combined with Docetaxel."